American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

Cancer statistics, 2018

Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · see citing works

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535 · see citing works

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,080 · see citing works

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · see citing works

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N. Y., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444 · see citing works

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Schlumberger, M. J., Tahara, M., Wirth, L. J., Robinson, B. G., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K. L., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,115 · see citing works

Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790 · see citing works

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · see citing works

Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

Durante, C., Haddy, N., Baudin, É., Leboulleux, S., Hartl, D. M., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J., de Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,670 · see citing works

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Brose, M. S., Nutting, C. M., Jarząb, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardière, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,664 · see citing works

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, É., Elisei, R., Jarząb, B., Vasselli, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,556 · see citing works

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

Landa, I., Ibrahimpašić, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Doğan, S., Ricarte‐Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,294 · see citing works

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

Bamford, S., Dawson, E., Forbes, S. A., Clements, J., Pettett, R., Doǧan, A., Flanagan, A. M., Teague, J. W., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,248 · see citing works

Cabozantinib in Progressive Medullary Thyroid Cancer

Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217 · see citing works

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176 · see citing works

Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028 · see citing works

Biologic and Clinical Perspectives on Thyroid Cancer

Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 1,009 · see citing works

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969 · see citing works

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 940 · see citing works

BRAF Mutation in Papillary Thyroid Carcinoma

Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 917 · see citing works

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Choi, Y., Schellens, J. H. M., Soria, J., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Urbanowitz, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 909 · see citing works

Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., ZANZONICO, P. B., Haque, S. S., Gavane, S. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843 · see citing works

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 827 · see citing works

Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

Wirth, L. J., Sherman, E. J., Robinson, B. G., Solomon, B., Kang, H., Lorch, J. H., Worden, F. P., Brose, M. S., Patel, J. D., Leboulleux, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005651 · Cited by 798 · see citing works

PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma

Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 780 · see citing works

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence

Xing, M., Liu, R., Liu, X., Murugan, A. K., Zhu, G., Zeiger, M. A., Pai, S. I., & Bishop, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5094 · Cited by 734 · see citing works

RAS Point Mutations and PAX8-PPARγ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma

Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 711 · see citing works

Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning

Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gönen, M., Strausś, H. W., Tuttle, R. M., Drucker, W. D., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 582 · see citing works

TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas

Melo, M., da Rocha, A. G., Vinagre, J., Batısta, R., Peixoto, J., Tavares, C., Celestino, R., de Almeida, A. P., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 552 · see citing works

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

Solomon, J. P., Linkov, I., Rosado, A., Mullaney, K. A., Rosen, E. Y., Frosina, D., Jungbluth, A. A., Zehir, A., Benayed, R., Drilon, A. E. D. C., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0324-7 · Cited by 547 · see citing works

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers

Pozdeyev, N. V., Gay, L. M., Sokol, E. S., Hartmaier, R. J., Deaver, K. E., Davis, S., French, J. D., Borre, P. V., LaBarbera, D. V., Tan, A. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0373 · Cited by 538 · see citing works

Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next‐generation sequencing assay

Nikiforov, Y. E., Carty, S. E., Chiosea, S. I., Coyne, C., Duvvuri, U., Ferris, R. L., Gooding, W. E., Hodak, S. P., LeBeau, S. O., Ohori, N. P., et al. (2014) · Cancer · doi:10.1002/cncr.29038 · Cited by 497 · see citing works

Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer

Nikiforova, M. N., Wald, A. I., Roy, S., Durso, M. B., & Nikiforov, Y. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2292 · Cited by 483 · see citing works

Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma

Barbet, J., Campion, L., Kraeber‐Bodéré, F., & Chatal, J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0044 · Cited by 407 · see citing works

Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules

Nikiforova, M. N., Mercurio, S., Wald, A. I., de Moura, M. B., Callenberg, K. M., Santana‐Santos, L., Gooding, W. E., Yip, L., Ferris, R. L., & Nikiforov, Y. E. (2018) · Cancer · doi:10.1002/cncr.31245 · Cited by 403 · see citing works

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0154 · Cited by 392 · see citing works

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

Chakravarty, D., Santos, E. B., Ryder, M. M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G. E., Kolesnick, R. N., Thin, T. H., Rosen, N. X., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 389 · see citing works

Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Brose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 387 · see citing works

Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019

Maniakas, A., Dadu, R., Busaidy, N. L., Wang, J. R., Ferrarotto, R., Lu, C. S., Williams, M. D., Gunn, G. B., Hofmann, M.-C. C., Cote, G. J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3362 · Cited by 385 · see citing works

Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*

Ruegemer, J. J., HAY, I. D., Bergstralh, E. J., Ryan, J. J., Offord, K. P., & Gorman, C. A. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-501 · Cited by 384 · see citing works

Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma: An Unusually High Prevalence of ras Mutations

Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d-9laj-trct-g6qd · Cited by 371 · see citing works

Rationale for Central and Bilateral Lymph Node Dissection in Sporadic and Hereditary Medullary Thyroid Cancer

Scollo, C., Baudin, É., Travagli, J., Caillou, B., Bellon, N., Leboulleux, S., & Schlumberger, M. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021713 · Cited by 366 · see citing works

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma

Romei, C., Ciampi, R., & Elisei, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.11 · Cited by 358 · see citing works

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

Haddad, R. I., Nasr, C. E., Bischoff, L. A., Busaidy, N. L., Byrd, D. R., Callender, G. G., Dickson, P. V., Duh, Q., Ehya, H., Goldner, W. S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0089 · Cited by 357 · see citing works

PD-1 Blockade in Anaplastic Thyroid Carcinoma

Capdevila, J., Wirth, L. J., Ernst, T., Ponce-Aix, S., Lin, C., Ramlau, R., Butler, M. O., Delord, J., Gelderblom, H. A. J., Ascierto, P. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02727 · Cited by 355 · see citing works

Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers

Yoo, S., Lee, S., Kim, S., Jee, H., Kim, B.-A., Cho, H., Song, Y. S., Cho, S. W., Won, J., Shin, J.-Y., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006239 · Cited by 353 · see citing works

Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer

García‐Rostán, G., Costa, Â. M., Pereira‐Castro, I., Salvatore, G., Hernández, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle‐Teijeiro, J., & Santoro, M. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 336 · see citing works

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Wagle, N., Grabiner, B. C., Allen, E. M. V., Amin‐Mansour, A., Taylor-Weiner, A. N., Rosenberg, M. W., Gray, N. S., Barletta, J. A., Guo, Y., Swanson, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403352 · Cited by 321 · see citing works

TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer

Liu, X., Qu, S., Liu, R., Sheng, C., Shi, X., Zhu, G., Murugan, A. K., Guan, H., Yu, H., Wang, Y., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4048 · Cited by 319 · see citing works

Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors

Gasparre, G., Porcelli, A. M., Bonora, E., Pennisi, L. F., Toller, M., Iommarini, L., Ghelli, A. M., Moretti, M., Betts, C. M., Martinelli, G. N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703056104 · Cited by 315 · see citing works

Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis

Hiltzik, D. M., Carlson, D. L., Tuttle, R. M., Chuai, S., Ishill, N. M., Shaha, A. R., Shah, J. P., Singh, B., & Ghossein, R. A. (2006) · Cancer · doi:10.1002/cncr.21739 · Cited by 313 · see citing works

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 285 · see citing works

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes

Ganly, I., Makarov, V., Vasudeva, S. D., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G. J., Eng, S., Bose, P., Kuo, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.002 · Cited by 283 · see citing works

Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer

Kelly, L. M., Barila, G., Liu, P., Evdokimova, V. N., Trivedi, S., Panebianco, F., Gandhi, M., Carty, S. E., Hodak, S. P., Luo, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321937111 · Cited by 268 · see citing works

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma

Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P. P., Livitz, D. G., Rosebrock, D., Sadow, P. M., Campbell, B., Donovan, S. E., Amin, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.013 · Cited by 266 · see citing works

Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy

Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., Takamura, Y., Higashiyama, T., Fukushima, M., Kihara, M., Inoue, H., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0355 · Cited by 263 · see citing works

NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology

Febbo, P. G., Ladanyi, M., Aldape, K., Marzo, A. M. D., Hammond, M. E. H., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 256 · see citing works

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers

Dunn, L. A., Sherman, E. J., Baxi, S. S., Tchekmedyian, V., Grewal, R. K., Larson, S. M., Pentlow, K. S., Haque, S. S., Tuttle, R. M., Sabra, M. M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01478 · Cited by 252 · see citing works

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing

Ciampi, R., Romei, C., Ramone, T., Prete, A., Tacito, A., Cappagli, V., Bottici, V., Viola, D., Torregrossa, L., Ugolini, C., et al. (2019) · iScience · doi:10.1016/j.isci.2019.09.030 · Cited by 242 · see citing works

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Iyer, P. C., Dadu, R., Gule-Monroe, M. K., Busaidy, N. L., Ferrarotto, R., Habra, M. A., Zafereo, M., Williams, M. D., Gunn, G. B., Grosu, H. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0378-y · Cited by 239 · see citing works

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF ^V600E </i> -Mutated Anaplastic Thyroid Carcinoma

Wang, J. R., Zafereo, M. E., Dadu, R., Ferrarotto, R., Busaidy, N. L., Lu, C., Ahmed, S., Gule-Monroe, M. K., Williams, M. D., Sturgis, E. M., et al. (2019) · Thyroid® · doi:10.1089/thy.2019.0133 · Cited by 230 · see citing works

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy

Hsiao, S. J., Zehir, A., Sireci, A. N., & Aisner, D. L. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.03.008 · Cited by 225 · see citing works

Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma

Rivera, M., Ghossein, R. A., Schöder, H. M., Gomez, D. R., Larson, S. M., & Tuttle, R. M. (2008) · Cancer · doi:10.1002/cncr.23515 · Cited by 209 · see citing works

Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF V600E Mutation

Kim, K. B., Cabanillas, M. E., Lazar, A. J., Williams, M. D., Sanders, D. L., Ilagan, J. L., Nolop, K. B., Lee, R. J., & Sherman, S. I. (2013) · Thyroid · doi:10.1089/thy.2013.0057 · Cited by 197 · see citing works

Management of invasive well‐differentiated thyroid cancer: An American head and neck society consensus statement: AHNS consensus statement

Shindo, M. L., Caruana, S. M., Kandil, E. H., McCaffrey, J. C., Orloff, L. A., Porterfield, J. R., Shaha, A. R., Shin, J. J., Terris, D. J., & Randolph, G. W. (2014) · Head & Neck · doi:10.1002/hed.23619 · Cited by 196 · see citing works

Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012

Carhill, A. A., Litofsky, D. R., Ross, D. S., Jonklaas, J., Cooper, D. S., Brierley, J. D., Ladenson, P. W., Ain, K. B., Fein, H. G., Haugen, B. R., et al. (2015) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2015-1346 · Cited by 184 · see citing works

Life Expectancy Is Reduced in Differentiated Thyroid Cancer Patients ≥ 45 Years Old with Extensive Local Tumor Invasion, Lateral Lymph Node, or Distant Metastases at Diagnosis and Normal in All Other DTC Patients

Verburg, F. A., Mäder, U., Tanase, K., Thies, E.-D., Dießl, S., Buck, A. K., Luster, M., & Reiners, C. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2458 · Cited by 181 · see citing works

Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma

Cabanillas, M. E., Ferrarotto, R., Garden, A. S., Ahmed, S., Busaidy, N. L., Dadu, R., Williams, M. D., Skinner, H. D., Gunn, G. B., Grosu, H. B., et al. (2018) · Thyroid · doi:10.1089/thy.2018.0060 · Cited by 159 · see citing works

SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon

Boichard, A., Croux, L., Ghuzlan, A. A., Broutin, S., Dupuy, C., Leboulleux, S., Schlumberger, M. J., Bidart, J., & Lacroix, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2092 · Cited by 152 · see citing works

Anaplastic thyroid cancer

O'Neill, J. P., & Shaha, A. R. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.440 · Cited by 152 · see citing works

JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

Yoshino, T., Pentheroudakis, G., Mishima, S., Overman, M. J., Yeh, K., Baba, E., Naito, Y., Calvo, F. M., Saxena, A. K., Chen, L.-T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.299 · Cited by 142 · see citing works

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine

Jaber, T., Waguespack, S. G., Cabanillas, M. E., Elbanan, M., Vu, T. H., Dadu, R., Sherman, S. I., Amit, M., Santos, E. B., Zafereo, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00612 · Cited by 142 · see citing works

Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase–Rearranged Anaplastic Thyroid Carcinoma

Godbert, Y., de Figueiredo, B. H., Bonichon, F., Chibon, F., Hostein, I., Pérot, G., Dupin, C., Daubech, A., Belleannée, G., Gros, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6596 · Cited by 142 · see citing works

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine

Nagarajah, J., Le, M., Knauf, J. A., Ferrandino, G., Montero‐Conde, C., Pillarsetty, N., Bolaender, A., Irwin, C., Krishnamoorthy, G. P., Saqcena, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci89067 · Cited by 141 · see citing works

Gene Fusions in Thyroid Cancer

Yakushina, V. D., Lerner, L. V., & Лавров, А. В. (2017) · Thyroid · doi:10.1089/thy.2017.0318 · Cited by 138 · see citing works

Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid

Chindris, A.-M., Casler, J. D., Bernet, V. J., Rivera, M., Thomas, C., Kachergus, J. M., Necela, B. M., HAY, I. D., Westphal, S. A., Grant, C. S., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1634 · Cited by 131 · see citing works

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy

Liu, J., Liu, Y., Lin, Y., & Liang, J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.215 · Cited by 129 · see citing works

Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol

Iravani, A., Solomon, B., Pattison, D. A., Jackson, P. A., Kumar, A. S. R., Kong, G., Hofman, M. S., Akhurst, T. J., & Hicks, R. J. (2019) · Thyroid · doi:10.1089/thy.2019.0143 · Cited by 124 · see citing works

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

Wirth, L. J., Brose, M. S., Sherman, E. J., Licitra, L. F., Schlumberger, M. J., Sherman, S. I., Bible, K. C., Robinson, B. G., Rodien, P., Godbert, Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03093 · Cited by 124 · see citing works

Application of Immunohistochemistry in Thyroid Pathology

Liu, H., & Lin, F. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0056-ra · Cited by 122 · see citing works

Relation of Doubling Time of Plasma Calcitonin Levels to Prognosis and Recurrence of Medullary Thyroid Carcinoma

Miyauchi, A., Onishi, T., Morimoto, S., Takai, S., Matsuzuka, F., Kuma, K., Maeda, M., & Kumahara, Y. (1984) · Annals of Surgery · doi:10.1097/00000658-198404000-00014 · Cited by 118 · see citing works

Alterations of the BRAF Gene in Thyroid Tumors

Ciampi, R., & Nikiforov, Y. E. (2005) · Endocrine Pathology · doi:10.1385/ep:16:3:163 · Cited by 117 · see citing works

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

Gambacorti-Passerini, C. B., Orlov, S., Zhang, L., Braiteh, F., Huang, H., Esaki, T., Horibe, K., Ahn, J., Beck, J. T., Edenfield, W. J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25043 · Cited by 114 · see citing works

Anaplastic thyroid carcinoma: review of treatment protocols

Tiedje, V., Stuschke, M., Weber, F., Dralle, H., Moss, L., & Führer, D. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0435 · Cited by 114 · see citing works

Studies of Allelic Loss in Thyroid Tumors Reveal Major Differences in Chromosomal Instability between Papillary and Follicular Carcinomas1

Ward, L. S., Brenta, G., Medvedovic, M., & Fagin, J. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4550 · Cited by 112 · see citing works

Clinical Course of Thyroid Carcinoma After Neck Dissection

Shah, M. D., Hall, F. T., Eski, S. J., Witterick, I., Walfish, P. G., & Freeman, J. L. (2003) · The Laryngoscope · doi:10.1097/00005537-200312000-00008 · Cited by 111 · see citing works

SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies

Saqcena, M., Leandro-Garcia, L. J., Mååg, J. L. V., Tchekmedyian, V., Krishnamoorthy, G. P., Tamarapu, P. P., Tiedje, V., Reuter, V. P., Knauf, J. A., de Stanchina, E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0735 · Cited by 109 · see citing works

Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

Marabelle, A., Fakih, M. G., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz253.018 · Cited by 104 · cited 9× · see citing works

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

Drilon, A. E. D. C., Subbiah, V., Oxnard, G. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.102 · Cited by 104 · see citing works

Prevalence and Prognostic Significance of Poor Differentiation and Tall Cell Variant in Papillary Carcinoma in Japan

Ito, Y., Hirokawa, M., Fukushima, M., Inoue, H., Yabuta, T., Uruno, T., Kihara, M., Higashiyama, T., Takamura, Y., Miya, A., et al. (2008) · World Journal of Surgery · doi:10.1007/s00268-007-9406-7 · Cited by 99 · see citing works

PAX8/PPARγ Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma

Armstrong, M. J., Yang, H., Yip, L., Ohori, N. P., McCoy, K. L., Stang, M. T., Hodak, S. P., Nikiforova, M. N., Carty, S. E., & Nikiforov, Y. E. (2014) · Thyroid · doi:10.1089/thy.2014.0067 · Cited by 96 · see citing works

Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules

Saleh, H. A., Jin, B. K., Barnwell, J., & Alzohaili, O. (2010) · Diagnostic Pathology · doi:10.1186/1746-1596-5-9 · Cited by 94 · see citing works

Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell‐derived thyroid carcinoma

Sabra, M. M., Sherman, E. J., & Tuttle, R. M. (2017) · Cancer · doi:10.1002/cncr.30690 · Cited by 91 · see citing works

Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.

Shah, M. H., Wei, L., Wirth, L. J., Daniels, G. A., de Souza, J. A., Timmers, C. D., Sexton, J., Beshara, M., Nichols, D., Snyder, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.6022 · Cited by 85 · see citing works

Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma

Sandulache, V. C., Williams, M. D., Lai, S. Y., Lu, C., William, W. N., Busaidy, N. L., Cote, G. J., Singh, R. R., Luthra, R., & Cabanillas, M. E. (2016) · Thyroid · doi:10.1089/thy.2016.0076 · Cited by 84 · see citing works

Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT

Dettmer, M. S., Schmitt, A. M., Steinert, H. C., Capper, D., Moch, H., Komminoth, P., & Perren, A. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0057 · Cited by 84 · see citing works

Prognostic Significance of Ki‐67 Labeling Index in Papillary Thyroid Carcinoma

Ito, Y., Miyauchi, A., Kakudo, K., Hirokawa, M., Kobayashi, K., & Miya, A. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0746-3 · Cited by 81 · see citing works

Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma

Lee, D. Y., Won, J., Lee, S., Park, D. J., Jung, K. C., Sung, M., Wu, H.-G., Kim, K. H., Park, Y. J., & Hah, J. H. (2015) · Thyroid · doi:10.1089/thy.2015.0316 · Cited by 80 · see citing works

Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors

Lamartina, L., Borget, I., Mirghani, H., Ghuzlan, A. A., Berdelou, A., Bidault, F., Deandreis, D., Baudin, É., Travagli, J., Schlumberger, M. J., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3284 · Cited by 78 · see citing works

Neoadjuvant selpercatinib for advanced medullary thyroid cancer

Jozaghi, Y., Zafereo, M., Williams, M. D., Gule-Monroe, M. K., Wang, J. R., Grubbs, E. G., Vaporciyan, A. J., Hu, M. I.-N., Busaidy, N. L., Dadu, R., et al. (2020) · Head & Neck · doi:10.1002/hed.26527 · Cited by 78 · see citing works

Is the incidence of anaplastic thyroid cancer increasing: A population based epidemiology study

Janz, T. A., Neskey, D. M., Nguyen, S. A., & Lentsch, E. J. (2018) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1016/j.wjorl.2018.05.006 · Cited by 77 · see citing works

BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry

Loo, E. Y., Khalili, P., Beuhler, K., Siddiqi, I. N., & Vasef, M. A. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000516 · Cited by 74 · see citing works

The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy

Kasaian, K., Wiseman, S. M., WALKER, B. A. M., Schein, J. E., Zhao, Y., Hirst, M., Moore, R. A., Mungall, A. J. J., Marra, M. A., & Jones, S. J. M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1955-9 · Cited by 72 · see citing works

Chromosomal Aberrations by Comparative Genomic Hybridization in Hurthle Cell Thyroid Carcinomas Are Associated with Tumor Recurrence

Wada, N., Duh, Q., Miura, D., Brunaud, L., Wong, M. G., & Clark, O. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020339 · Cited by 69 · see citing works

Anaplastic thyroid cancer

Ranganath, R., Shah, M. A., & Shah, A. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000189 · Cited by 61 · see citing works

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.

Subbiah, V., Hu, M. I.-N., Gainor, J. F., Mansfield, A. S., Alonso, G., Taylor, M. H., Zhu, V. W., Garrido, P., Amatu, A., Doebele, R. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.109 · Cited by 60 · see citing works

Ki-67 Labeling Index Is a Predictor of Postoperative Persistent Disease and Cancer Growth and a Prognostic Indicator in Papillary Thyroid Carcinoma

Miyauchi, A., Kudo, T., Hirokawa, M., Ito, Y., Kihara, M., Higashiyama, T., Yabuta, T., Masuoka, H., Shindo, H., Kobayashi, K., et al. (2013) · European Thyroid Journal · doi:10.1159/000347148 · Cited by 59 · see citing works

Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma

Zagzag, J., Pollack, A. Z., Dultz, L. A., Dhar, S. I., Ogilvie, J. B., Heller, K. S., Deng, F.-M., & Patel, K. N. (2013) · Surgery · doi:10.1016/j.surg.2013.06.020 · Cited by 54 · see citing works

Therapeutic breakthroughs for metastatic thyroid cancer

Tiedje, V., & Fagin, J. A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0307-2 · Cited by 53 · see citing works

Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with BRAF V600E Mutational Analysis

Bernstein, J., Virk, R. K., Hui, P., Prasad, A., Westra, W. H., Tallini, G., Adeniran, A., Udelsman, R., Sasaki, C. T., Roman, S. A., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0154 · Cited by 52 · see citing works

Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma

Smith, A. L., Williams, M. D., Stewart, J., Wang, W., Krishnamurthy, S., Cabanillas, M. E., & Roy‐Chowdhuri, S. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21992 · Cited by 51 · see citing works

A Relook at the T Stage of Differentiated Thyroid Carcinoma with a Focus on Gross Extrathyroidal Extension

Song, E., Lee, Y., Oh, H., Jeon, M. J., Song, D. E., Kim, T. Y., Kim, W. B., Shong, Y. K., Sung, T., & Kim, W. G. (2018) · Thyroid · doi:10.1089/thy.2018.0300 · Cited by 50 · see citing works

Liquid Biopsy in Thyroid Cancer: New Insight.

Khatami, F., & Tavangar, S. M. (2018) · Europe PMC (PubMed Central) · Cited by 48 · see citing works

Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer

Xu, J. Y., Handy, B. C., Michaelis, C., Waguespack, S. G., Hu, M. I.-N., Busaidy, N. L., Jiménez, C., Cabanillas, M. E., Fritsche, H. A., Cote, G. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2567 · Cited by 46 · see citing works

Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study

Iwasaki, H., Yamazaki, H., Takasaki, H., Suganuma, N., Nakayama, H., Toda, S., & Masudo, K. (2018) · Oncology Letters · doi:10.3892/ol.2018.9553 · Cited by 45 · see citing works

Allelotyping of Follicular Thyroid Carcinoma: Frequent Allelic Losses in Chromosome Arms 7q, 11p, and 22q

Kitamura, Y., Shimizu, K., Ito, K., Tanaka, S., & Emi, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4268 · Cited by 44 · see citing works

Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

Parker, K. G., White, M. G., & Cipriani, N. A. (2020) · Head and Neck Pathology · doi:10.1007/s12105-020-01166-8 · Cited by 44 · see citing works

Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers

Genutis, L. K., Tomšič, J., Bundschuh, R. A., Brock, P. L., Williams, M. D., Roychowdhury, S., Reeser, J. W., Frankel, W. L., Alsomali, M., Routbort, M. J., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0655 · Cited by 43 · see citing works

A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer

Ljubas, J., Ovesen, T., & Rusan, M. (2019) · Cancers · doi:10.3390/cancers11070943 · Cited by 43 · see citing works

Molecular features of thyroid oncocytic tumors

Gasparre, G., Bonora, E., Tallini, G., & Romeo, G. C. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.02.022 · Cited by 42 · see citing works

PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma

Wei, S., LiVolsi, V. A., Montone, K. T., Morrissette, J. J. D., & Baloch, Z. W. (2015) · Endocrine Pathology · doi:10.1007/s12022-015-9403-6 · Cited by 40 · see citing works

Everolimus in Anaplastic Thyroid Cancer: A Case Series

Harris, E. J., Hanna, G. J., Chau, N. G., Rabinowits, G., Haddad, R. I., Margalit, D. N., Schoenfeld, J. D., Tishler, R. B., Barletta, J. A., Nehs, M. A., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00106 · Cited by 40 · see citing works

Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

Taylor, M. H., Gainor, J. F., Hu, M. I.-N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6018 · Cited by 39 · see citing works

Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib

Leroy, L., Bonhomme, B., Moulec, S. L., Soubeyran, I., Italiano, A., & Godbert, Y. (2019) · Thyroid · doi:10.1089/thy.2019.0202 · Cited by 37 · see citing works

The Impact of Metastatic Lymph Nodes on Risk Stratification in Differentiated Thyroid Cancer: Have We Reached a Higher Level of Understanding?

Urken, M. L., Haser, G. C., Likhterov, I., & Wenig, B. M. (2016) · Thyroid · doi:10.1089/thy.2015.0544 · Cited by 36 · see citing works

Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction

Koyama, S., Miyake, N., Fujiwara, K., Morisaki, T., Fukuhara, T., Kitano, H., & Takeuchi, H. (2018) · European Thyroid Journal · doi:10.1159/000485972 · Cited by 36 · see citing works

First Tissue-Agnostic Drug Approval Issued

(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-078 · Cited by 36 · see citing works

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer

Huillard, O., Tenenbaum, F., Clerc, J., Goldwasser, F., & Groussin, L. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1114 · Cited by 34 · see citing works

A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma

Hillier, K., Hughes, A. L., Shamberger, R. C., Shusterman, S., Pérez‐Atayde, A. R., Wassner, A. J., Iafrate, A. J., Dubuc, A. M., Janeway, K. A., Rothenberg, S. M., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0041 · Cited by 33 · see citing works

Comprehensive Transcriptomic and Genomic Profiling of Subtypes of Follicular Variant of Papillary Thyroid Carcinoma

Song, Y. S., Won, J., Yoo, S., Jung, K. C., Kim, M. J., Kim, S., Cho, S. W., Lee, K. E., Yi, K. H., Seo, J., et al. (2018) · Thyroid · doi:10.1089/thy.2018.0198 · Cited by 32 · see citing works

CirculatingBRAFV600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma

Iyer, P. C., Cote, G. J., Hai, T., Gule-Monroe, M. K., Bui, J. H., Williams, M. D., Hess, K. R., Hofmann, M.-C. C., Dadu, R., Zafereo, M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00173 · Cited by 28 · see citing works

Registrational results of LOXO-292 in patients with RET-altered thyroid cancers

Wirth, L. J., Sherman, E. J., Drilon, A. E. D. C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.093 · Cited by 27 · see citing works

Recent advances and emerging therapies in anaplastic thyroid carcinoma

Cabanillas, M. E., Zafereo, M., Williams, M. D., Ferrarotto, R., Dadu, R., Gross, N. D., Gunn, G. B., Skinner, H. D., Cote, G. J., Grosu, H. B., et al. (2018) · F1000Research · doi:10.12688/f1000research.13124.1 · Cited by 25 · see citing works

Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings

Jeong, S. H., Hong, H. S., Kwak, J. J., & Lee, E. H. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0311-x · Cited by 25 · see citing works

Impact of superior mediastinal metastasis on the prognosis of papillary thyroid carcinoma

Moritani, S. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0677 · Cited by 25 · see citing works

The Role of postoperative external beam radiotherapy for differentiated thyroid carcinoma: A Systematic review and meta‐analysis

Jacomina, L. E., Jacinto, J. K. M., Co, L. B. A., Yu, K. K. L., Agas, R. A. F., Co, J. L., & Mejia, M. B. A. (2020) · Head & Neck · doi:10.1002/hed.26133 · Cited by 24 · see citing works

Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer

Kim, M. J., Kim, S., Lee, E. K., Hwangbo, Y., Lee, Y. J., Cho, S. W., Park, D. J., Lee, Y., & Park, Y. J. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0488 · Cited by 21 · see citing works

Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer

Obata, K., Sugitani, I., Ebina, A., Sugiura, Y., Toda, K., Takahashi, S., & Kawabata, K. (2016) · International Cancer Conference Journal · doi:10.1007/s13691-016-0257-7 · Cited by 20 · see citing works

Establishment of a cell line with variantBCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia

Inokuchi, K., Shinohara, T., Futaki, M., Hanawa, H., Tanosaki, S., Yamaguchi, H., Nomura, T., & Dan, K. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199811)23:3 · Cited by 16 · see citing works

Chemotherapy for Anaplastic Thyroid Cancer

Lessin, L. S. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-995-0_85 · Cited by 2 · see citing works

Pathology of Anaplastic Carcinoma

Baloch, Z. W., & LiVolsi, V. A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3314-3_96 · Cited by 2 · see citing works

1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer

Cabanillas, M. E., Drilon, A., Farago, A. F., Brose, M. S., McDermott, R., Sohal, D., Oh, D.-Y., Almubarak, M., Bauman, J., Chu, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1404

442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Keam, B., Hu, M. I., Subbiah, V., Wirth, L., Schuler, M., Mansfield, A. S., Brose, M. S., Curigliano, G., Leboulleux, S., Zhu, V. W., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.434

Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival.

Wang, J. R., Cote, G. J., Zafereo, M., Iyer, P. C., Dadu, R., Busaidy, N. L., Gross, N. D., Sturgis, E. M., Ferrarotto, R., Lu, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6023

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)

Keam, B., Kreitman, R. J., Wainberg, Z. A., Cabanillas, M. E., Cho, D. C., Italiano, A., Stein, A., Cho, J. Y., Schellens, J. H. M., Wen, P. Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy302.002

Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).

Sherman, E. J., Tsai, C. J., Zhi, W. I., Fetten, J. V., Wu, V., Ho, A. L., Riaz, N., Pfister, D. G., & Lee, N. Y. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6088

Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy.

Khan, S. A., Kurian, P., Mobley, B., Burks, T., Beg, M. S., Ross, J. S., Ali, S. M., & Bowles, D. W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e18114

A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).

Lorch, J. H., Barletta, J. A., Nehs, M., Uppaluri, R., Alexander, E. K., Haddad, R. I., Hanna, G. J., Margalit, D. N., Tishler, R. B., Schoenfeld, J. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.6513

Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).

Cabanillas, M. E., Dadu, R., Ferrarotto, R., Liu, S., Fellman, B. M., Gross, N. D., Gule-Monroe, M., Lu, C., Grosu, H., Williams, M. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.6514

NTRK1-3 point mutations in poor prognosis thyroid cancers.

Iniguez-Ariza, N. M., Bible, K. C., Morris, J. C., Chintakuntlawar, A. V., Shridhar, V., Smallridge, R. C., Menefee, M. E., Hilger, C., Severson, E. A., & Ryder, M. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.6087

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response

Rothenberg, S., Daniels, G., & Wirth, L. (2015) · Clinical cancer research : an official journal of the American Association for Cancer Research · doi:10.1158/1078-0432.ccr-15-2298

Photodynamic Therapy for Thyroid Cancer

Inglot, J., Strzelczyk, J. K., Bartusik-Aebisher, D., & Aebisher, D. (2025) · BioMed · doi:10.3390/biomed5010008 · Cited by 2 · see citing works